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Abstract. The GLI-Krüppel zinc finger factor yin yang-1 
(YY1) is a complex protein that regulates a variety of 
processes including transcription, proliferation, development 
and differentiation. YY1 inhibits cell growth in a cell type-
specific manner. The role played by YY1 in its control of 
tumor cell growth is unclear and controversial. We show here 
that YY1 can suppress the growth of different tumor cell types 
in vitro, including human breast carcinoma cells and glio-
blastoma cells. YY1 also blocked the growth of 13762 MAT 
mammary adenocarcinoma isografts in rats. YY1 inhibited 
13762 MAT tumor growth by approximately 80% compared 
with the GFP alone group 21 days after injection. YY1 inhib-
ited proliferating cell nuclear antigen (PCNA) expression and 
pRbSer249/Thr252 phosphorylation without influencing tumor 
microvascular density. Moreover, YY1 inhibited p21WAF1/Cip1 
complex formation with cdk4 and cyclin D1. These findings 
demonstrate that YY1 can negatively regulate the growth of 
multiple malignant cell types.
Introduction
Yin yang-1 (YY1) is a ubiquitous and multifunctional tran-
scription factor (also known as delta, NF-E1, UCRBP, and 
CF1) belonging to the C2H2 subclass of GLI-Krüppel zinc 
finger proteins. YY1 was cloned and characterized initially 
by two independent groups (1,2). The YY1 gene resides on 
human chromosome 14 at segment q32.2 and consists of five 
highly-conserved exons which undergo alternative splicing 
and encode four C2H2 motifs (3). YY1 protein contains both 
activation and repression domains at the amino-terminus and 
carboxyl-terminus, respectively. YY1 plays a role in transcrip-
tional initiation, activation and repression (4). Physiologically, 
YY1 is required for a variety of processes including embryo-
genesis, growth and differentiation (4). However, the role of 
YY1 in cancer growth is poorly defined.
We previously demonstrated that YY1 is induced by 
mechanical injury of rat arteries and exposure of vascular 
smooth muscle cells to growth factors such as fibroblast growth 
factor-2 (5). YY1 overexpression inhibited vascular smooth 
muscle cell growth in culture (5) and intimal hyperplasia in rat, 
rabbit and human blood vessels (6). Interestingly, YY1 does 
not appear to influence vascular endothelial cell growth (5,6). 
The role played by YY1 in its control of tumor cell growth is 
unclear and controversial.
Here we demonstrate that YY1 can suppress the growth 
of different tumor cell types in vitro, including human breast 
carcinoma cells and human glioblastoma cells. Moreover, YY1 
blocked solid tumor growth in rats, inhibited proliferating 
cell nuclear antigen (PCNA) expression and pRbSer249/Thr252 
phosphorylation without influencing tumor microvascular 
density. These findings show that YY1 can negatively regulate 
the growth of multiple malignant cell types. 
Materials and methods
Cell proliferation assays. Human MCF7 breast carcinoma 
cells, human U178 glioblastoma cells and rat 13762 MAT 
mammary adenocarcinoma cells were obtained from the 
American Type Culture Collection (ATCC) and grown in 
RPMI-1640, pH 7.4, containing 10% FBS with antibiotics 
(7). Cells in 96-well plates (3000 cells seeded), were rendered 
growth quiescent by incubation in serum-free medium for 
24 h. The cells were transfected with the indicated amounts 
of plasmid or transduced with the indicated amounts of 
adenoviral constructs, Ad-LacZ or Ad-YY1 (6) in 10% FBS/
DMEM, pH 7.4. After 2 or 3 days (as indicated), the cells were 
trypsinized, resuspended in Isoton II and quantified using a 
Coulter counter.
Western blot analysis. Samples were resolved by electro-
phoresis using denaturing SDS-polyacrylamide gels for 2 h 
at 100 V. Proteins were transferred to Immobilon P nylon 
membranes (Millipore) prior to incubation with non-fat 
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skim milk to block non-specific binding sites.  Membranes 
were incubated with the indicated antibodies (Santa Cruz 
Biotechnology). Detection was achieved with HRP-linked 
secondary antibodies at a dilution of 1:1000 and chemilumi-
nescence (Perkin-Elmer).
Construction of retroviral YY1, transduction of 13762 MAT 
mammary adenocarcinoma cells and primary tumor growth 
in rats. YY1 cDNA, produced by restriction of pCB6-YY1 
with EcoRI, was ligated into the EcoRI site of the murine 
stem cell virus-long terminal repeat (MSCV-LTR) retroviral 
vector pKMV upstream of an internal ribosome entry site 
(IRES) and enhanced green fluorescence protein (EGFP). 
The resultant construct YY1-pKMV, or pKMV alone, was 
transfected into the Phoenix ecotropic packaging cell line 
using calcium phosphate and cultured in DMEM containing 
10% FBS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/
ml streptomycin (Life Technologies). Supernatant containing 
replication-defective virus was collected 2 days post transfec-
tion and used to transduce (www.stanford.edu/group/nolan/
protocols/pro_helper_dep.html) the rat mammary adenocar-
cinoma 13762 MAT cell line (8) maintained in RPMI-1640 
containing 10% FBS, 2 mM glutamine, 100 U/ml penicillin 
and 100 µg/ml streptomycin (Life Technologies). Two days 
post-infection, EGFP+ cells were sorted by flow cytometry and 
used in primary tumor growth experiments. Female Fischer 
344 rats (10-13 w.o.) were injected subcutaneously with 1x106 
13762 MAT cells transduced previously with YY1-pKMV or 
pKMV alone in 100 µl of RPMI-1640 containing 10% FBS. 
After 21 days, the rats were sacrificed and primary tumors 
removed, weighed and fixed in formalin. Microvascular 
density was evaluated by blinded microscopic examination of 
6 entire H&E-stained cross-sections under high power field 
each from 3 tumors per group. Five animals were used in each 
group, and the experiment was performed twice.
Immunohistochemical staining. Staining was performed 
with antibodies on consecutive paraffin sections of formalin-
fixed tissues. Prior to staining, deparaffinized sections were 
boiled in citrate buffer, pH 6.0, to retrieve antigenicity, and 
treated with 3% hydrogen peroxide. After washing with PBS, 
pH 7.4, sections were incubated with primary antibody for 
1 h, followed by incubation with the secondary antibody (goat 
anti-rabbit; BA-1000: Vector) or horse anti-mouse BA-2000 
for 1 h and finally with avidin-biotin complex (Elite ABC kit; 
PK-6100, Vector). Bound avidin-biotin complexes were visual-
ized by treatment with 3,3'-diaminobenzidine (DAB) solution 
for 2 min, which produced brown coloration. Sections were 
counterstained with Mayer's hematoxylin.
Immunoprecipitation analysis. Cells were transfected with 
indicated constructs, and after 24 h, harvested in 1X RIPA 
buffer and precleared with prewashed protein G-sepharose 
beads for 1 h prior to incubation with the indicated primary 
antibody for 1 h at 4˚C with gentle shaking. Pre-washed sepha-
rose beads were incubated with the lysate/antibody mixture for 
a further 2 h. Beads were washed several times with 1X RIPA 
followed by a final wash with 200 mM NaCl/RIPA. Proteins 
were resolved by 12.5% SDS-PAGE and immunodetected by 
Western blot analysis.
Animal ethics and statistics. Animal experiments were 
conducted with the approval of the Animal Ethics Committee of 
John Curtin School of Medical Research, Australian National 
University (Canberra, Australia). Values are expressed as the 
mean + SEM. Differences between groups were tested for 
statistical significance using ANOVA as indicated in the text 
and considered significant at p<0.05.
Results
YY1 suppressed tumor cell growth. We introduced exogenous 
YY1 into MCF7 human breast carcinoma cells in culture using 
either a CMV-based plasmid (pCB6+) or by adenovirus (pAd-
Easy).  Exposure of growth-quiescent MCF7 cells to medium 
containing serum increased cell proliferation within 3 days 
(Fig. 1). YY1 significantly inhibited MCF7 proliferation, 
following delivery by either plasmid (Fig. 1, left) or adenovirus 
(Fig. 1, right).  In contrast, neither transfection with equivalent 
amounts of plasmid backbone, nor transduction with the LacZ 
adenovirus perturbed MCF7 cell growth (Fig. 1). In support 
of these data, YY1 overexpression confirmed by Western blot-
ting, reduced levels of PCNA (Fig. 1, upper right), a marker 
of cell growth.  YY1 inhibition of tumor cell growth was not 
confined to human breast carcinoma cells. Transduction of 
U178 human glioblastoma cells with YY1 resulted in signifi-
cant, dose-dependent inhibition of serum-inducible tumor cell 
growth within 3 days (Fig. 2, left). Western blotting further 
confirmed that YY1 was overexpressed in the transduced cells 
(Fig. 2, right).
YY1 suppressed 13762 MAT tumor growth in rats without 
influencing tumor microvascular density. To evaluate the 
influence of YY1 on tumor growth in an animal model we 
transduced 13762 MAT rat mammary adenocarcinoma 
cells with a green fluorescent protein (GFP)-based retro-
viral construct generating YY1. GFP+ cells were sorted by 
flow cytometry and implanted subcutaneously into rats. 
YY1 inhibited MAT tumor growth by approximately 80% 
compared with the GFP alone group 21 days after injection 
(Fig. 3A, right), a growth inhibitory effect that was clearly 
evident visually (Fig. 3A, upper left). This growth inhibitory 
effect was not due to YY1 suppression of tumor angiogenesis. 
Assessment of microvascular density in the resected tumors 
did not demonstrate a difference between the Retro-GFP-YY1 
and Retro-GFP groups despite the significant difference in 
tumor size (Fig. 3A, right, inset). In support of YY1 suppres-
sion of 13762 MAT tumor growth in vivo, YY1 significantly 
inhibited serum-inducible 13762 MAT cell proliferation 
in vitro and did so in a dose-dependent fashion (Fig. 3A, lower 
left).
YY1 suppressed PCNA expression and pRb phosphorylation in 
13762 MAT tumors. pRb phosphorylation inactivates pRb and 
permits cell cycle progression (9). We therefore investigated 
whether YY1-dependent growth inhibition in the 13762 MAT 
tumors caused reduction in levels of pRb phosphorylation. 
Immunohistochemical staining revealed that YY1 was 
indeed overexpressed in the Retro-GFP-YY1 tumors. This in 
turn reduced both pRbSer249/Thr252 expression and resulted in a 
concomitant reduction in PCNA (Fig. 3B).

























































































































YY1 suppressed p21WAF1/Cip1 expression and inhibited p21WAF1/Cip1 
complex formation with cdk4 and cyclin D1. Since Rb phos-
phorylation lies downstream of a p21WAF1/Cip1-cdk4-cyclin D1 
cell cycle regulatory complex 6, we determined the effect of 
YY1 on p21WAF1/Cip1 complex formation with cdk4 and cyclin D1. 
YY1 overexpression, which was confirmed by Western blotting, 
reduced p21WAF1/Cip1 expression in 13762 MAT cells (Fig. 3C). 
Moreover, immunoprecipitation studies revealed that YY1 
reduced intracellular levels of p21WAF1/Cip1-cdk4 and p21WAF1/Cip1-
cyclin D1 complexes (Fig. 3C), presumably via down regulating 
p21WAF1/Cip1 expression. YY1 overexpression did not affect total 
levels of cyclin D1, cdk4 or β-actin (Fig. 3C). YY1 therefore 
inhibits tumor growth and pRb phosphorylation, and inhibits 
formation of a cell cycle regulatory complex.
Figure 1. YY1 suppresses MCF7 cell proliferation. MCF7 cells were transfected with the indicated amount of pCB6+ or pCB6-YY1 (left panel), or transduced 
with Ad-LacZ or Ad-YY1 (right panel). After 3 days the cells were trypsinized, resuspended in Isoton II, and quantified using a Coulter counter. No Tx denotes 
no treatment. In vitro proliferation experiments were performed in triplicate. Vertical bars represent ± SEM, *p<0.05. Alternatively, YY1 and PCNA protein 
levels were determined 24 h after transduction with 10 MOI of Ad-YY1 or Ad-LacZ by Western blot analysis (top right panel). 
Figure 2. YY1 suppresses U178 cell proliferation. U178 cells were transduced with various amounts of Ad-YY1, and after 3 days the cells were trypsinized, 
resuspended and quantified (left). No Tx denotes no treatment. SFM denotes serum-free medium. In vitro proliferation experiments were performed in tripli-
cate. Vertical bars represent ± SEM, *p<0.05. Alternatively, U178 cells were transduced with 10 MOI of Ad-YY1 or Ad-LacZ and after 24 h Western blotting 
was performed for YY1 expression (right). 


























































































































The role of YY1 in cancer cell growth is controversial.  On 
the one hand, YY1 has been implicated in cell cycle progres-
sion, tumor cell resistance to chemotherapeutic agents and 
in the initiation of tumorigenesis (10-12). For example, YY1 
physically interacts with Hdm2 and the tumor suppressor p53, 
and stimulate Hdm2-mediated p53 polyubiquitination and 
degradation (13). YY1 also negatively regulates Fas and death 
receptor-5 (DR5) in several tumor cell types (14). Nitric oxide 
increases Fas expression via inactivation of YY1 binding 
to the silencer region of the Fas promoter (14). Moreover 
  A
  B
Figure 3. YY1 suppresses 13762 MAT tumor growth in rats without influencing tumor microvascular density. Rat 13762 MAT adenocarcinoma cells were 
transduced with retroviral-GFP-YY1 (pKMV-YY1) or retroviral-GFP (pKMV) prior to sorting for GFP+ cells by flow cytometry and subcutaneous implanta-
tion in rats. (A) Tumors from each cohort were resected after 21 days, weighed and data expressed as mean tumor weight (right). Representative gross images of 
tumors (upper left). The inset represents blinded quantification of blood vessel density per high power field in the tumors. Alternatively, 13762 MAT cells were 
transfected in vitro with the indicated amounts of pcDNA3 or pcDNA3-YY1. After 2 days the total number of cells in the wells were collected and resuspended 
in Isoton II, and quantified using a Coulter counter (lower left). No Tx denotes no treatment. In vitro proliferation experiments were performed in triplicate. 
Vertical bars represent ± SEM, *p<0.05. (B) Immunostaining of the 13762 MAT tumors for YY1, PCNA and pRbSer249/Thr252. Antibodies were used at a dilution 
of 1:200 (YY1, PCNA, p-pRbSer249/Thr252). (C) 13762 MAT cells were transfected with 30 µg pcDNA3 or pcDNA3-YY1 and after 24 h, extracts were subjected 
either to Western blot (Wst) analysis for cdk4, cyclin D1, YY1 or p21WAF1/Cip1, or immunoprecipitation (IP) with p21WAF1/Cip1 antibodies followed by blotting 
for cdk4 or cyclin D1. SFM, serum-free medium.
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chemotherapeutic drug-induced sensitization of tumor cells 
to TRAIL-mediated apoptosis (by CDDP, ADR, etoposide, 
vincristine) involves inhibition of YY1 and up-regulation 
of DR5 expression (15). Elevated YY1 protein levels are 
associated with a number of cancer types such as high-grade 
squamous cervical intraepithelial lesions, cervical cancer and 
HPV infection of the cervix (16). This has led to the sugges-
tion that YY1 may serve as a diagnostic and prognostic tumor 
marker, and a drug target in cancer therapy (11).
The present findings support YY1 serving an alterna-
tive role, namely acting as a tumor suppressor at least in an 
overexpression setting. A recent study also demonstrates that 
YY1 overexpression inhibits breast cancer (MDA-MB-231) 
xenograft growth in nude mice and suggests that YY1 may 
serve as a tumor suppressor for breast cancer formation (17). 
Lee et al compared YY1 expression between breast cancer and 
normal breast tissue and found the majority of normal tissues 
examined had higher YY1 levels than tumors (17). In certain 
other tumors such as adenocarcinoma and melanoma, YY1 
expression is reduced compared to benign and normal counter-
parts (18). YY1 is expressed comparatively lower in metastatic 
malignant melanoma than malignant melanoma, and again in 
pediatric osteosarcoma versus normal osteoblasts (18). Lastly, 
while YY1 may be involved in prostate cancer development, 
decreased YY1 may give metastatic cells a survival advantage 
(19). Our studies show that YY1 can negatively regulate the 
growth of multiple malignant cell types.
Our findings suggest that YY1 inhibition of 13762 MAT 
cell growth involves its suppression of p21WAF1/Cip1 expression 
and inhibition of complex formation between p21WAF1/Cip1 and 
cdk4, and p21WAF1/Cip1-cyclin D1. pRb phosphorylation and 
PCNA are well-established markers of tumor cell prolifera-
tion (20,21) and both factors are suppressed by YY1. PCNA 
was originally identified as an antigen that is expressed in the 
nuclei of cells during S-phase (22) and is now known to clamp 
DNA polymerase δ to DNA (23). pRb phosphorylation inacti-
vates this tumor suppressor, releasing E2F and facilitating cell 
cycle progression (6,24). Alternatively, or even in addition, 
YY1, as a transcriptional repressor, may inhibit the expres-
sion of endogenous growth factors and cytokines required for 
autocrine tumor cell growth, or even increase the expression 
of growth inhibitors. For example, YY1 binds to and represses 
the promoter of EGF (25) which, through its receptor EGF-R, 
has been widely implicated in tumor progression, invasion 
and metastasis (26). Other mechanisms may also be at play. 
YY1 is a potent positive regulator of BRCA1 gene expression, 
which is generally reduced in sporadic breast cancer (17). In 
addition, YY1 activates HLJ1, a novel tumor and invasion 
suppressor that inhibits tumorigenesis and cancer metastasis 
(27).
Our inability to detect differences in microvascular density 
between the YY1-transduced and control tumor groups is 
consistent with our previous demonstration that YY1 does not 
inhibit vascular endothelial cell growth (5,6). This suggests 
that YY1 suppression of tumor growth is direct, rather than 
indirect via inhibition of a vascular supply.
In summary, we show here that YY1 can inhibit the 
growth of different tumor cell types in vitro, and block solid 
tumor growth in rats, inhibit PCNA expression and reduce 
pRbSer249/Thr252 phosphorylation. These findings show that YY1 
can negatively regulate the growth of multiple malignant cell 
types.
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